v3.26.3
LIQUIDITY (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
LIQUIDITY      
Net loss   $ 77,586 $ 74,412
Net cash used in operating activities   64,635 69,075
Accumulated deficit $ 481,442 481,442 403,856
Cash and cash equivalents 10,615 10,615 94,107
Short-term investments 97,186 97,186 73,751
Total liabilities 12,162 12,162 13,363
Current liabilities 11,418 11,418 $ 11,912
XOMA (US) LLC | US Clinical Trial Rz358 (ersodetug) | Ersodetug License Agreement | Upon Regulatory Approval      
LIQUIDITY      
Milestone closing payment   $ 25,000  
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Ersodetug License Agreement      
LIQUIDITY      
Milestone closing payment $ 5,000